Related Experiment Video
Updated: Jul 12, 2025

Left Coronary Artery Ligation: A Surgical Murine Model of Myocardial Infarction
Published on: August 9, 2022
Lipoprotein(a) and Long-Term Recurrent Infarction After an Acute Myocardial Infarction
Gema Miñana1, Alberto Cordero2, Lorenzo Fácila3
1Cardiology Department, Hospital Clínico Universitario de Valencia, Universitat de Valencia, INCLIVA, Valencia, Spain; Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares (CIBERCV), Madrid, Spain; Universitat de Valencia, Valencia, Spain.
Insights
Elevated Lipoprotein(a) (Lp[a]) levels in patients hospitalized for acute myocardial infarction (AMI) predict a higher risk of long-term recurrent AMI. This finding highlights Lp[a] as a crucial marker for risk stratification in AMI survivors.
Area of Science:
- Cardiology
- Biomarkers
- Cardiovascular Disease
Background:
- Lipoprotein(a) (Lp[a]) is an established risk factor for incident ischemic heart disease.
- The role of Lp[a] in risk stratification for in-hospital survivors of acute myocardial infarction (AMI), particularly for long-term recurrent AMI, is less understood.
Purpose of the Study:
- To investigate the association between Lp[a] levels and the risk of very long-term recurrent AMI after an initial AMI event.
- To assess Lp[a] as a predictor for recurrent myocardial infarction in a long-term follow-up cohort.
Main Methods:
- Retrospective analysis of 1,223 consecutive patients with AMI discharged between October 2000 and June 2003.
- Lp[a] levels were measured during index hospitalization.
- Negative binomial regression was used to evaluate the relationship between Lp[a] at discharge and total recurrent AMI over a median follow-up of 9.9 years.
Main Results:
- Lp[a] levels were not associated with increased long-term all-cause mortality (p=0.934).
- A significant positive and nonlinear association was found between Lp[a] levels and the risk of total long-term reinfarction (p=0.016).
- No differential effect of Lp[a] was observed in prevalent subgroups.
Conclusions:
- Elevated Lp[a] levels measured during hospitalization for AMI are associated with an increased risk of recurrent myocardial infarction in the very long term.
- Lp[a] may serve as a valuable biomarker for identifying AMI survivors at high risk for future reinfarction.
- Further prospective studies are needed to confirm these findings and explore clinical implications.
Abstract:
Lipoprotein(a) (Lp[a]) is an emerging risk factor for incident ischemic heart disease. However, its role in risk stratification in in-hospital survivors to an index acute myocardial infarction (AMI) is scarcer, especially for predicting the risk of long-term recurrent AMI. We aimed to assess the relation between Lp(a) and very long-term recurrent AMI after an index episode of AMI. It is a retrospective analysis that included 1,223 consecutive patients with an AMI discharged from October 2000 to June 2003 in a single-teaching center. Lp(a) was assessed during index admission in all cases. The relation between Lp(a) at discharge and total recurrent AMI was evaluated through negative binomial regression. The mean age of the patients was 67.0 ± 12.3 years, 379 (31.0%) were women, and 394 (32.2%) were diabetic. The index event was more frequently non-ST-segment elevation myocardial infarction (66.0%). The median Lp(a) was 28.8 (11.8 to 63.4) mg/100 ml. During a median follow-up of 9.9 (4.6 to 15.5) years, 813 (66.6%) deaths and 1,205 AMI in 532 patients (43.5%) occurred. Lp(a) values were not associated with an increased risk of long-term all-cause mortality (p = 0.934). However, they were positively and nonlinearly associated with an increased risk of total long-term reinfarction (p = 0.016). In the subgroup analysis, there was no evidence of a differential effect for the most prevalent subgroups. In conclusion, after an AMI, elevated Lp(a) values assessed during hospitalization were associated with an increased risk of recurrent reinfarction in the very long term. Further prospective studies are warranted to evaluate their clinical implications.
More Related Videos
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Inflammation
Peripheral Artery Disease I: Introduction
Atherosclerosis I: Introduction
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

